Clinical Trials on EBV Lymphomas

Total 8832 results

Fondazione Italiana Linfomi - ETS

Active, not recruiting

Indolent Non Follicular Lymphomas Prognostic Project

Indolent B-Cell Lymphomas

France, Italy, Brazil, Austria, Portugal, Ukraine
University of Washington
Genentech, Inc.

Suspended

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich... and other conditions

United States
Peking University
University of Florida

Unknown

Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas (4SCAR19273)

B-cell Lymphomas

China
ADC Therapeutics S.A.

Withdrawn

Long-term Registry of Patients Treated With Loncastuximab Tesirine

B-Cell Lymphomas

United States
Grupo Español de Linfomas y Transplante Autólogo...

Completed

Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients

B-Cell Lymphomas

Spain
Ahmed Galal, MD

Withdrawn

Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ)

B Cell Lymphomas

United States
University of Minnesota

Completed

Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients

CMV Viremia | EBV Viremia

United States
University Hospital, Basel, Switzerland

Recruiting

Occurrence of Antibodies Cross-reacting With Autoantigens in Primary EBV Infection

Epstein-Barr Virus (EBV) Infection

Switzerland
Oncology Specialists, S.C.
University of Illinois at Chicago

Terminated

Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas

Non-Hodgkin Lymphomas

United States
Fudan University

Unknown

Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) (FAD)

Chemotherapy | T-Cell Lymphomas

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases (MALTED)

Nasopharyngeal Carcinoma | Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Leiomyosarcoma | Lymphoproliferative Disorder | Severe Chronic Active EBV (SCAEBV)

United States
The First Hospital of Jilin University

Unknown

A Perspective Study of the Antiviral Efficacy and Safety of Switching to TAF Treatment in CHB Adults With Suboptimal Response (SOR) and Intolerant to Entecavir

HBV
Institute of Liver and Biliary Sciences, India

Withdrawn

'Tenofovir Pulse and Peg Interferon Alpha 2b' Therapy in HBeAg-positive Patients With Normal ALT

HBV

India
Yi-Hua Zhou
The First People's Hospital of Kunshan; Taixing People's Hospital; Fourth People... and other collaborators

Completed

Telbivudine Therapy in HBeAg-positive Pregnant Women to Prevent Mother-to-infant Transmission of HBV

HBV

China
Dong-A University Hospital
Samsung Medical Center; Asan Medical Center; Chonnam National University Hospital and other collaborators

Completed

Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)

B-cell Lymphomas

Korea, Republic of
Memorial Sloan Kettering Cancer Center
University of Nebraska

Completed

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

T-cell Lymphomas | Relapsed or Refractory

United States
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute; Stanford University

Active, not recruiting

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Lymphoma | Relapsed/Refractory T-cell Lymphomas

United States
National Health Research Institutes, Taiwan
National Taiwan University Hospital; China Medical University Hospital; Chang... and other collaborators

Not yet recruiting

Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas

Peripheral T-cell Lymphomas (PTCL)

Taiwan
Samsung Medical Center
Janssen Medical Affairs

Completed

Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas

Non-Hodgkin Lymphoma | Peripheral T-Cell Lymphomas

Korea, Republic of
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL

Epstein-Barr Virus-Related Hodgkin Lymphoma | Epstein-Barr Virus-Related Non-Hodgkin Lymphoma | EBV Positive Plasma Cell Neoplasm

United States
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor Prognosis (CUTALLO)

Epidermotropic T-cell Lymphomas

France
Lorenzo Gallon
Bristol-Myers Squibb

Completed

Belatacept 3 Month Post Transplant Conversion Study

EBV | Transplant; Failure, Kidney

United States
Bristol-Myers Squibb

Recruiting

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 in Participants With Relapsed or Refractory T-cell Lymphomas in Japan

Relapsed or Refractory T-cell Lymphomas

Japan
University of Pennsylvania

Completed

Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas

Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas

United States
Eureka Therapeutics Inc.
Duke University; Duke Clinical Research Institute

Terminated

Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

Lymphomas Non-Hodgkin's B-Cell

United States
University Hospital, Brest
Teva Pharmaceuticals USA

Terminated

Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine. (MYLY)

Cerebral Lymphoma B Cell Refractory

France
Centre de Recherches et d'Etude sur la Pathologie...

Completed

Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies (HepB20)

HBV

France
Aucta Pharmaceuticals, Inc

Completed

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects

HBV

Australia
Nanjing NingQi Medicine Science and Technology...
Jiangsu Cancer Institute & Hospital

Unknown

Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study

Peripheral T-cell Lymphomas

China
The Lymphoma Academic Research Organisation

Completed

The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas ((RAD001-R))

Non-Hodgkin's Lymphomas

France
Yogen Saunthararajah

Completed

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

T-cell Lymphoma | Indolent B-cell Lymphoma | Aggressive B-cell Lymphoma | Non-Hodgkin's Lymphomas

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection

Indolent B-Cell Non-Hodgkin's Lymphomas

China
Yale University
Merck Sharp & Dohme LLC

Terminated

Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas

Relapsed Lymphomas | Refractory Lymphomas

United States
CHU de Reims

Unknown

Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions (RADIO-LYMPH)

Indolent Cutaneous B Cell Lymphomas

France
National Cancer Institute (NCI)

Recruiting

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Immune System Diseases | Lymphoproliferative Disorders | Peripheral T-cell Lymphomas

United States
Antengene Biologics Limited

Recruiting

A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

Advanced Solid Tumors | B-cell Non-Hodgkin Lymphomas

United States
Dana-Farber Cancer Institute
HiberCell, Inc.

Completed

A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas

United States
Beijing Friendship Hospital

Not yet recruiting

Response Prediction in EBV-HLH Using Metabonomics Analysis

EBV | Hemophagocytic Lymphohistiocytoses | Metabonomics

China
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Plasmablastic Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell... and other conditions

United States
Ontario Clinical Oncology Group (OCOG)
Sunnybrook Health Sciences Centre; Genzyme, a Sanofi Company

Completed

Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas (ACCAPELA)

Peripheral T-cell Lymphomas

Canada
Affiliated Hospital of Nantong University

Not yet recruiting

Obinutuzumab in Chinese Real-world Patients With iNHL

Lymphomas Non-Hodgkin's B-Cell

China
Austin Health
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study (AvR-CHOP)

Lymphomas Non-Hodgkin's B-Cell

Australia
IGM Biosciences, Inc.

No longer available

Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL

Relapsed/Refractory Non-Hodgkin Lymphomas

Australia, Korea, Republic of, Spain
Poitiers University Hospital

Completed

Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin Lymphoma

High Grade Lymphomas CD20 Positive

France
Beijing Friendship Hospital

Not yet recruiting

PD-1 Antibody for Reactive EBV After BMT

Transplant | EBV Infection | PD-1

China
Fondazione Italiana Linfomi ONLUS

Completed

Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)

B-Cell Lymphomas

Italy, Brazil
IRCCS San Raffaele
Mundipharma K.K.

Unknown

High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement (SCNSL1)

B-Cell Lymphomas

Italy
National Cancer Institute (NCI)

Recruiting

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Kaposi Sarcoma | Viral Associated Malignancies | EBV/KSHV-associated Lymphomas

United States
State Budgetary Healthcare Institution, National...

Unknown

BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation (BeEAC-1)

Relapsed/Refractory Malignant Lymphomas

Russian Federation
Gruppo Italiano Studio Linfomi

Completed

HDS Plus PBPC Transplant Vs 4 More Courses of FrontLine Therapy in Pts With Aggressive NHL in PR After Induction Therapy

High-Grade Lymphomas

Italy

Clinical Trials on EBV Lymphomas

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations